Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanqi Qushi Granule (SQG) is a traditional Chinese medicine formulation used primarily for the treatment of nephrotic syndrome and idiopathic membranous nephropathy. It has demonstrated clinical efficacy in alleviating proteinuria and protecting podocytes from injury, which are key pathological features in nephrotic syndrome. The mechanism of action involves inhibition of kidney cell apoptosis and protection against podocyte damage via modulation of the PI3K/AKT signaling pathway. SQG is being studied in multicenter, randomized, double-blind, placebo-controlled clinical trials to evaluate its safety and efficacy in patients with idiopathic membranous nephropathy and primary nephrotic syndrome. It is derived from herbal components including Panax notoginseng root (Sanqi).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanqi Qushi Granule.